Initial studies from Kebir et al. evidenced the upregulation of IL-22R in the brains of MS patients and the role of IL-22 in synergy with IL-17A in disrupting the integrity of BBB tight junctions by reducing the expression of occludin in endothelial cells [71]. This evidence concerns the gene IL17A and myeloid sarcoma.